ArticleTropical medicine and health2026
A pilot study evaluating the tolerability and effectiveness of miltefosine and sodium stibogluconate for the treatment of cutaneous leishmaniasis in Kandahar, Afghanistan.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
backgroundOral miltefosine (MF) achieves per-protocol cure rates of 68-77% against Leishmania tropica in Iran and Pakistan, but it has never been compared with the standard of care in Afghanistan, where only intralesional (IL) or intramuscular (IM) antimonials are used. We, therefore, assessed the 6-month efficacy and tolerability of sodium stibogluconate (SSG) and MF, including MF pharmacokinetics, in L. tropica-predominant Kandahar city.
methodsThis single-centre, open-label, pilot trial randomised patients aged ≥5 years to either SSG or 28-day, partially supervised MF that was allometrically scaled from the adult dose of 2.5 mg/kg/day. For the SSG group, patients were treated with either IL-SSG ×1/week ×5 doses or IM-SSG 20 mg/kg/day x20d for IL-inaccessible lesions. All children < 5 years received MF in an observational arm. Epithelialisation of ulcerated lesions or return to normal skin for other lesions, with resolution of signs of acute inflammation, defined cure.
resultsOf 103 recruited patients (65 males), 15 were randomised to IL-SSG, 27 to IM-SSG, and 37 to MF; 24 under-5 s received MF. Respective median (interquartile range) ages were: 11.9 (7.2-13.8), 9.9 (8.2-15.1), 10 (7.8-12.5) and 4.3 (2.9-4.9) years. A total of 113/191 (59.2%) lesions were located on the face. 66 patients completed the 6-month follow-up. Combining the MF groups, the Kaplan-Meier cure rates (95% confidence intervals) were MF 25.3 (14.7‒40.9)%, IL-SSG 65.0 (36.0‒91.5)% (p=0.019 vs. MF), and IM-SSG 77.3 (53.7‒94.3)% (p=0.001 vs. MF). Median MF exposures
conclusionsSSG was effective by both routes, but partially supervised MF was ineffective. More work is needed to determine factors affecting MF effectiveness against L. tropica in Kandahar. Clinical trial number The clinical trial number is TCTR20180710007, dated 10/07/2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.